# Carnegie

> Carnegie is a VC fund in Stockholm backing Health Care and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 7
- Last investment: Dec 2021
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/carnegie-investment-bank
- X (Twitter): https://twitter.com/kunskapsbanken
- Website: http://www.carnegie.se/en
- Facebook: https://www.facebook.com/carnegiefonder

Carnegie is a VC fund in Stockholm focused on Health Care and Medical. Carnegie is one of the most prominent financial advisors and asset managers in the Nordic region. Their main divisions are both among the market leaders within their respective sectors, and through their dynamic business model, they leverage the synergies between the two to add additional value to their customers. They are independent in order toguarantee highly qualitative research and advice to institutions, corporations and private individuals. Carnegie operates in seven countries and has approximately 650 employees.Carnegie Securities targets institutional clients and offers services within research, equity sales, sales trading and equity capital market transactions. Carnegie’s top-ranked research and equity sales cover about 300 Nordic companies and enjoy a globally leading position in Nordic equities. Operations in Denmark, Finland, Norway, the UK, Sweden and the US. Carnegie Investment Banking offers professional advisory services in mergers and acquisitions (M&A) and equity capital market (ECM) transactions. Carnegie has a long-established local presence, with unique understanding and expertise concerning industries and equity markets in the Nordic region. Primary markets are Denmark, Finland, Norway and Sweden.Carnegie Private Banking & Investment Solutions provides comprehensive financial advisory services to high net worth individuals, small businesses and foundations. Their team of experts understand the details that add up the client’s day-to-day concerns: family law, foundation trusteeship, tax management, pensions, management and equity sales, all under the same roof. Markets: Denmark, Luxembourg and Sweden.

## Contacts

5 contacts available for Carnegie. Shizune tracks 4 team members at Carnegie. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/carnegie?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Manufacturing | 2 | 29% |
| Pharmaceutical | 2 | 29% |
| Genetics | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 43% |
| Private Equity | 2 | 29% |
| Funding Round | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 2 | 29% |
| United States | 2 | 29% |
| Canada | 1 | 14% |
| Norway | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bjorn Jansson | CEO | 0 | — |
| David Carnegie, Sr. | Founder | 0 | — |
| Mikael Tjäder | General Manager - Third Party Distribution | 0 | — |
| Spyros Chandrinos | Student | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Occlutech | Occlutech, founded in 2003, is a rapidly expanding European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants. The company has developed several new, unique products using a wide range of state of the art technological capabilities and proprietary know-how. | $49.3M | Private Equity | Dec 21, 2021 |  |
| Doktor.se | Doktor.se is a modern and personal care company working with digital healthcare. They are in an expansive phase, they have several offices in Sweden and grow sharply.With experienced specialist nurses, doctors and psychologists, they help their members to get quick and effective care. Their goal is to deliver a whole new level of service withinSwedish care.They help with counseling, book doctor hours, distance care, recipes, referrals, and much more. They always follow every case through their app. They also provide exclusive care and health offers as well as collecting interesting articles and news that will suit the clients.Doktor.se is an approved healthcare provider its counseling and booking are carried out by certified healthcare professionals and specialists in their area. Doktor.se also owns physical primary care and has extensive experience in Swedish healthcare. | $61.2M | Venture - Series Unknown | May 31, 2021 |  |
| Doktor.se | Doktor.se is a modern and personal care company working with digital healthcare. They are in an expansive phase, they have several offices in Sweden and grow sharply.With experienced specialist nurses, doctors and psychologists, they help their members to get quick and effective care. Their goal is to deliver a whole new level of service withinSwedish care.They help with counseling, book doctor hours, distance care, recipes, referrals, and much more. They always follow every case through their app. They also provide exclusive care and health offers as well as collecting interesting articles and news that will suit the clients.Doktor.se is an approved healthcare provider its counseling and booking are carried out by certified healthcare professionals and specialists in their area. Doktor.se also owns physical primary care and has extensive experience in Swedish healthcare. | $49.6M | Series C | May 27, 2020 |  |
| Agilyx | We believe the time is right to expand advanced recycling, giving post-use plastic a new, circular life by converting this valuable material back into its original building blocks for reuse. By enabling plastic circularity on a global and commercial scale, we aim to play a vital role in accelerating the shift to a low-carbon economy. We haveco-founded Cyclyx International, Inc, a waste plastics management company, to work directly with industry participants to engineer customized plastic recovery programs that supply advanced and chemical recycling facilities. | $9.3M | Private Equity | Jan 18, 2020 |  |
| Corus Pharma | Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of thecompany are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma.Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006. | $65M | Series C | Apr 13, 2004 |  |
| Galileo Genomics | Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest suchpopulation worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations. | $9M |  | Jan 08, 2004 |  |
| CyLex | Cylex is a life science company and a leader in the development and manufacture of unique products that use the immune system for predicting and managing human health. It is the first and only company to offer a patent- protected, FDA-cleared cellular assay of immune system function, ImmuKnow(TM), which measures the vitality of a patient'simmune system from a single drop of blood. The company's products enable physicians to better manage and personalize the treatment of life-threatening diseases, such as HIV, HCV, cancer, diabetes, autoimmune and other disorders, as well as serious conditions associated with organ transplantation. | $12.8M | Series C | Jun 15, 2000 |  |

7 of 7 investments shown.

## Co-investors
- Oriola — VC Fund, 3 deals together
- [Bonnier Capital](https://shizune.co/investors/profile/bonnier-ventures) — VC Fund, 2 deals together
- [Svenska Handelsbanken](https://shizune.co/investors/profile/handelsbanken) — VC Fund, 2 deals together
- AVP Holdings — VC Fund, 1 deal together
- [Antares Capital](https://shizune.co/investors/profile/antares-capital) — VC Fund, 1 deal together
- [Anthem Venture Partners](https://shizune.co/investors/profile/anthem-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Carnegie invest in?

Carnegie invests primarily in Health Care, Medical and Manufacturing startups, most often at Series C and Private Equity stage. Most of the 7 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Carnegie?

Public channels for Carnegie include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Carnegie?

The team at Carnegie includes Bjorn Jansson (CEO), David Carnegie, Sr. (Founder) and Mikael Tjäder (General Manager - Third Party Distribution). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co